EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systematic Pathway Screening via Integrated Machine Learning Identifies FOXO‐Mediated Transcription Signature for Robust Immunotherapy Response Prediction in Non–Small Cell Lung Cancer

Shuqi Wu, Chenxi Deng, Chaofan Fan iD, Qiheng Liang, Lingxuan Zhu iD, Weiming Mou iD, Hongsen Huang, Keren Wu, Yizhang Li, Gengwen Deng, Liling Xu, Jiarui Xie und 11 weitere

Human Mutation · 2026

DOI: 10.1155/humu/8690530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, 2026. Verfasst von Shuqi Wu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China, fimmu.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Forkhead Transcription Factors, Machine Learning. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Commission of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non–small cell lung cancer (NSCLC), accounting for 80% of lung cancer cases, remains a leading cause of cancer‐related mortality globally. While immune checkpoint inhibitors (ICIs) have improved outcomes, their efficacy is limited to a subset of patients, necessitating robust biomarkers for personalized immunotherapy response prediction.

Methods

We integrated transcriptomic data from 584 NSCLC patients across four cohorts treated with ICIs. Using 12,025 pathways from MSigDB, we applied 101 machine learning algorithm combinations (e.g., random survival forest [RSF], least absolute shrinkage and selection operator [Lasso], and Cox proportional hazards model with component‐wise likelihood‐based boosting [CoxBoost]) to identify prognostic signatures. OAK was used as the training set and Ravi, Jung, and Poplar as the validation set. The optimal pathway and algorithm combination was determined based on the average concordance index ( C ‐index) ranking in the validation sets, and a predictive model was generated. Performance was assessed by C ‐index, receiver operating characteristic (ROC) analysis, and survival analysis. Biological relevance was evaluated through gene set enrichment analysis (GSEA), immune infiltration profiling, and immunohistochemistry (IHC).

Results

The FOXO‐mediated transcription pathway combined with Lasso‐RSF algorithms emerged as the top predictor. The derived FOXO‐related signature (FRS) stratified patients into high‐risk and low‐risk groups, with high‐risk patients showing significantly worse progression‐free survival (PFS) and overall survival (OS) across all cohorts ( p < 0.05). FRS outperformed clinical variables and 43 published models in predictive accuracy. IHC confirmed elevated expression of FRS‐associated genes (PCK1, IGFBP1) in nonresponders. Immune profiling revealed enriched antitumor immunity in low‐FRS patients.

Conclusion

FRS, a machine learning–derived pathway signature, robustly predicts immunotherapy response and survival in NSCLC. Its integration of FOXO‐mediated immune regulation offers a clinically translatable tool for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsForkhead Transcription FactorsMachine LearningImmunotherapyHumansGene Expression Regulation, NeoplasticPrognosisBiomarkers, TumorFemaleGene Expression ProfilingMaleTranscriptome

Stichwörter der Autor:innen

FOXO-mediated transcription pathwayimmune checkpointsimmune infiltrationimmunotherapynon–small cell lung cancer

Substanzen

Forkhead Transcription FactorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
  • The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
  • Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
  • School of Stomatology, Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.
  • Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, shsmu.edu.cn.
  • The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China, fimmu.com.

ORCID-Profile: Chaofan Fan, Lingxuan Zhu, Weiming Mou, Chenglin Hong, Peng Luo, Aimin Jiang, Anqi Lin, Xin Chen

Förderung

  • National Health Commission of the People's Republic of China

Zitieren

APA

Wu, S., Deng, C., Fan, C., Liang, Q., Zhu, L., Mou, W., Huang, H., Wu, K., Li, Y., Deng, G., Xu, L., Xie, J., Hong, C., Deng, Y., Li, X., Wu, C., Yang, T., Luo, P., Wong, H. Z. H., …, & Ren, M. (2026). Systematic Pathway Screening via Integrated Machine Learning Identifies FOXO‐Mediated Transcription Signature for Robust Immunotherapy Response Prediction in Non–Small Cell Lung Cancer. Human Mutation. https://doi.org/10.1155/humu/8690530

Vancouver

Wu S, Deng C, Fan C, Liang Q, Zhu L, Mou W, et al. Systematic Pathway Screening via Integrated Machine Learning Identifies FOXO‐Mediated Transcription Signature for Robust Immunotherapy Response Prediction in Non–Small Cell Lung Cancer. Human Mutation. 2026. doi:10.1155/humu/8690530

BibTeX
@article{Wu2026,
  author = {Wu, Shuqi and Deng, Chenxi and Fan, Chaofan and Liang, Qiheng and Zhu, Lingxuan and Mou, Weiming and Huang, Hongsen and Wu, Keren and Li, Yizhang and Deng, Gengwen and Xu, Liling and Xie, Jiarui and Hong, Chenglin and Deng, Yuhang and Li, Xingjian and Wu, Changda and Yang, Tao and Luo, Peng and Wong, Hank Z H and Jiang, Aimin and Lin, Anqi and Chen, Xin and Ren, Minghua},
  title = {Systematic Pathway Screening via Integrated Machine Learning Identifies FOXO‐Mediated Transcription Signature for Robust Immunotherapy Response Prediction in Non–Small Cell Lung Cancer},
  journal = {Human Mutation},
  year = {2026},
  doi = {10.1155/humu/8690530}
}
Kostenlos starten →